DashboardPortfoliosFavoritenGemeinschaftEntdeckenSuchen
NOT FOR DISTRIBUTION
Loading...
  • Bestände
  • /
  • Materialien
Vor 1m aktualisiert
ANURAS logo

Anupam Rasayan India LtdNSEI:ANURAS Aktienübersicht

Marktkapitalisierung ₹140.0b
Vor 1m aktualisiert
Aktienkurs
n/a
1Y12.4%
7D-0.7%
1D0.1%
Wert des Portfolios
​
Siehe

Anupam Rasayan India Ltd

NSEI:ANURAS Lagerbericht

Marktkapitalisierung: ₹140.0b

  • Unternehmensüberblick
  • Bewertung
  • Ausblick und Wachstum
  • Leistungs-Rückblick
  • Finanzlage
  • Dividende
  • Management
  • Eigentümerschaft
  • Weitere Informationen
  • Aktien-Community

Anupam Rasayan India (ANURAS) Aktienübersicht

Anupam Rasayan India Ltd. beschäftigt sich mit der Auftragssynthese und Herstellung von Spezialchemikalien in Indien, Europa, Japan, Singapur, China, Nordamerika und auf internationaler Ebene. Mehr Details

ANURAS grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung0/6
Künftiges Wachstum5/6
Vergangene Leistung4/6
Finanzielle Gesundheit3/6
Dividenden1/6

Belohnungen

Prognostiziertes Gewinnwachstum 40.75% pro Jahr

Die Erträge stiegen im vergangenen Jahr um 41.5%

Risikoanalyse

Bei unseren Risikoprüfungen wurden keine Risiken für ANURAS festgestellt.

ANURAS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

AN
AnalystConsensusTarget
1.3% überbewertet intrinsischer Abschlag
AnalystConsensusTarget
•21d ago

ANURAS: Slowing Revenue Expansion Will Pressure Margins Despite Profit Recovery

81
0
0
AN
AnalystHighTarget
26.7% unterbewertet intrinsischer Abschlag
AnalystHighTarget
•3mo ago

Green Specialty Chemical Trends And China+1 Shifts Will Spark Expansion

32
0
1
AN
AnalystLowTarget
53.9% überbewertet intrinsischer Abschlag
AnalystLowTarget
•2mo ago

US Tariffs And Global Green Trends Will Compress Margins

28
0
2

Top Analyst Narratives

AN
AnalystConsensusTarget
1.3% überbewertet intrinsischer Abschlag
AnalystConsensusTarget
•21d ago

ANURAS: Slowing Revenue Expansion Will Pressure Margins Despite Profit Recovery

81
0
0
AN
AnalystHighTarget
26.7% unterbewertet intrinsischer Abschlag
AnalystHighTarget
•3mo ago

Green Specialty Chemical Trends And China+1 Shifts Will Spark Expansion

32
0
1
AN
AnalystLowTarget
53.9% überbewertet intrinsischer Abschlag
AnalystLowTarget
•2mo ago

US Tariffs And Global Green Trends Will Compress Margins

28
0
2
View all narratives

Anupam Rasayan India Ltd Wettbewerber

Privi Speciality Chemicals

Symbol: BSE:530117
Market cap: ₹138.1b

Vinati Organics

Symbol: BSE:524200
Market cap: ₹138.7b

Supreme Petrochem

Symbol: BSE:500405
Market cap: ₹152.9b

Aarti Industries

Symbol: BSE:524208
Market cap: ₹180.3b

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Anupam Rasayan India
Historische Aktienkurse
Aktueller Aktienkurs₹1,231.10
52-Wochen-Hoch₹1,415.00
52-Wochen-Tief₹1,045.20
Beta0.11
1 Monat Veränderung1.80%
3 Monate Veränderung-1.54%
1 Jahr Veränderung12.39%
3 Jahre Veränderung28.37%
5 Jahre Veränderung65.67%
Veränderung seit IPO133.69%

Aktuelle Nachrichten und Updates

User avatar
Narrative-Update • Aug 19

ANURAS: New Supply Agreements And Product Launch Will Shape Balanced Outlook

Analysts have lifted their price target for Anupam Rasayan India to about ₹1,215 from roughly ₹1,143, citing updated assumptions on revenue growth, profit margins and a lower future P/E multiple in their models. What's in the News for Anupam Rasayan India Anupam Rasayan India has scheduled a board meeting on August 14, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Analyseartikel • Aug 19

Revenue Beat: Anupam Rasayan India Ltd Exceeded Revenue Forecasts By 25% And Analysts Are Updating Their Estimates

Anupam Rasayan India Ltd ( NSE:ANURAS ) last week reported its latest first-quarter results, which makes it a good time...
User avatar
Narrative-Update • Jul 21

ANURAS: New Debt Plan Will Pressure Sentiment Despite Long-Term Supply Potential

Analysts have raised their price target for Anupam Rasayan India from ₹1,065 to ₹1,143, citing updated valuation work that reflects a slightly lower discount rate and a revised future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News Anupam Rasayan India signed a non-binding Letter of Intent with BASQUEVOLT, a European solid-state lithium battery developer based in Spain, to explore supplying a specialty chemical product for up to 10 years, with potential cumulative revenue of US$300 million, subject to product development and a definitive supply agreement.

Recent updates

User avatar
Narrative-Update • Aug 19

ANURAS: New Supply Agreements And Product Launch Will Shape Balanced Outlook

Analysts have lifted their price target for Anupam Rasayan India to about ₹1,215 from roughly ₹1,143, citing updated assumptions on revenue growth, profit margins and a lower future P/E multiple in their models. What's in the News for Anupam Rasayan India Anupam Rasayan India has scheduled a board meeting on August 14, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Analyseartikel • Aug 19

Revenue Beat: Anupam Rasayan India Ltd Exceeded Revenue Forecasts By 25% And Analysts Are Updating Their Estimates

Anupam Rasayan India Ltd ( NSE:ANURAS ) last week reported its latest first-quarter results, which makes it a good time...
User avatar
Narrative-Update • Jul 21

ANURAS: New Debt Plan Will Pressure Sentiment Despite Long-Term Supply Potential

Analysts have raised their price target for Anupam Rasayan India from ₹1,065 to ₹1,143, citing updated valuation work that reflects a slightly lower discount rate and a revised future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News Anupam Rasayan India signed a non-binding Letter of Intent with BASQUEVOLT, a European solid-state lithium battery developer based in Spain, to explore supplying a specialty chemical product for up to 10 years, with potential cumulative revenue of US$300 million, subject to product development and a definitive supply agreement.
User avatar
Narrative-Update • Jul 07

ANURAS: New Credit Issuance Will Pressure Sentiment Despite Recent Platform Milestone

Analysts have lifted their price target for Anupam Rasayan India from ₹976.43 to ₹1,065.00, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News Anupam Rasayan India announced it has become the first company globally to commercialise ETFA (Ethyl trifluoroacetate) using a proprietary continuous flow chemistry platform.
User avatar
Narrative-Update • Jun 23

ANURAS: Planned Debt Expansion Will Sustain An Unfavorable Risk Profile

Analysts have lifted their fair value estimate for Anupam Rasayan India from ₹640.00 to ₹800.00, reflecting updated assumptions on revenue growth, profit margins and future P/E multiples. What’s in the News for Anupam Rasayan India Anupam Rasayan India announced the commercialisation of ETFA (Ethyl trifluoroacetate) using its proprietary continuous flow chemistry platform, positioning the company as the first globally to produce ETFA at commercial scale using flow technology.
User avatar
Narrative-Update • Jun 08

ANURAS: Upcoming Debt Raise And Subsidiary Guarantees Will Support Future Upside

Analysts have inched up their fair value estimate for Anupam Rasayan India from ₹1,667.80 to ₹1,680.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The board has scheduled a meeting on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to recommend a final dividend for FY 2025-26.
User avatar
Narrative-Update • May 25

ANURAS: Planned Debt Issuance Will Sustain An Unfavorable Risk Profile

Analysts have lifted their price target on Anupam Rasayan India from ₹625 to ₹640, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of this change. What's in the News A board meeting is scheduled for May 23, 2026 at 12:45 IST to review and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend on equity shares for FY 2025-26 (company filing).
User avatar
Narrative-Update • May 06

ANURAS: Upcoming Overseas Subsidiary Guarantees Will Support Future Upside

Analysts have slightly adjusted their price target for Anupam Rasayan India to around ₹1,668, reflecting updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News A special shareholders meeting is scheduled for May 7, 2026 via postal ballot to seek approval for guarantees and security interests linked to the credit facility of wholly owned subsidiary Doriath S.à.r.l. This may include security over the shares and assets of Doriath S.à.r.l and Jayhawk Fine Chemicals Corporation (company filing).
User avatar
Narrative-Update • Apr 21

ANURAS: Upcoming Board Actions On Overseas Units Will Support Future Upside

Analysts have kept their fair value estimate for Anupam Rasayan India broadly unchanged at about ₹1,668, citing slight tweaks to the discount rate, revenue growth, profit margin and future P/E inputs that together support this stable price target view. What's in the News A board meeting is scheduled on Feb 12, 2026, to consider 12,000 shares of Doriath S.à r.l.; 1,800 shares of Batam S.à r.l. representing a 15% equity stake; potential credit facility transactions; an ECB facility agreement with Axis Bank Limited, IBU GIFT City; appointment of Axis Trustee Services Limited as security trustee; and other matters (Key Developments).
User avatar
Narrative-Update • Apr 07

ANURAS: Overseas Subsidiary Financing Structure Will Support Future Upside Potential

Analysts have nudged their fair value estimate for Anupam Rasayan India to about ₹1,668. This change is linked to updated assumptions on discount rate, revenue growth, profit margin and future P/E.
User avatar
Narrative-Update • Mar 23

ANURAS: Upcoming Credit Facilities And Subsidiary Transactions Will Pressure Sentiment Through 2026

The analyst price target for Anupam Rasayan India has been revised from ₹922 to ₹976, with analysts citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples to support the new view. What's in the News Board meeting on Feb 12, 2026 to review 12,000 shares of Doriath S.à r.l., a wholly owned subsidiary, and 1,800 shares of Batam S.à r.l. representing a 15% equity stake in Batam (Key Developments).
User avatar
Narrative-Update • Mar 09

ANURAS: Overseas Acquisitions And Expanded Borrowing Capacity Will Drive Future Upside

Analysts have nudged their fair value estimate for Anupam Rasayan India to about ₹1,668 per share, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and future P/E that leave the overall valuation picture broadly unchanged. What's in the News A board meeting is scheduled for Feb 12, 2026 to review the potential acquisition of 12,000 shares of Doriath S.à r.l. and 1,800 shares of Batam S.à r.l. representing 15% equity in Batam, and to consider new credit facilities and related security arrangements with Axis Bank Limited and Axis Trustee Services Limited (Key Developments).
User avatar
Narrative-Update • Feb 23

ANURAS: Future Overseas Acquisitions And Borrowing Headroom Will Redefine Upside Potential

Analysts have lifted their fair value estimate for Anupam Rasayan India from ₹1,305.00 to about ₹1,667.80, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Board meeting on Feb 12, 2026 to review acquisition of 12,000 shares of Doriath S.à r.l., a wholly owned subsidiary, and 1,800 shares in Batam S.à r.l. representing a 15% equity stake, along with related credit facility arrangements, including an ESCB Facility with Axis Bank Limited, IBU GIFT City, and appointment of Axis Trustee Services Limited as security trustee under an ECB Facility (company board notice).
User avatar
Narrative-Update • Feb 08

ANURAS: Planned Acquisition And Higher Leverage Will Sustain An Unfavorable Risk Profile

Analysts have kept their fair value estimate for Anupam Rasayan India steady at ₹625.00 per share, highlighting slightly adjusted assumptions around discount rate, revenue growth and profit margin as the key drivers behind the unchanged target. What's in the News A board meeting is scheduled for Feb 14, 2026 to consider and approve unaudited financial results for the quarter and nine months ended Dec 31, 2025, providing the next formal update on recent financial performance (company filing).
User avatar
Narrative-Update • Jan 25

ANURAS: Planned Acquisition And Higher Leverage Will Drive An Unfavorable Risk Profile

Analysts have raised their price target on Anupam Rasayan India from ₹520 to ₹625, citing updated assumptions for profit margins, growth and P/E that they consider better reflect the stock’s risk profile and return outlook. What's in the News Board meeting on Dec 09, 2025 to consider and approve the acquisition of Monitchem Kansas S.à r.l and its subsidiaries, along with a related loan receivable from CABB GmbH, and the execution of a Sale and Purchase Agreement (company filing).
Analyseartikel • Jan 21

Investors Met With Slowing Returns on Capital At Anupam Rasayan India (NSE:ANURAS)

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...
User avatar
Narrative-Update • Jan 08

ANURAS: Planned Acquisition And Higher Leverage Will Pressure Sentiment Through 2026

Analysts have lifted their fair value estimate for Anupam Rasayan India from ₹905 to about ₹922, citing updated assumptions for the discount rate, long term revenue growth, profit margins and the future P/E multiple. What's in the News The board will meet on Dec 09, 2025 to consider and approve the acquisition of Monitchem Kansas S.à r.l and its subsidiaries, along with a related loan receivable from CABB GmbH, and to authorize a Sale and Purchase Agreement and postal ballot notice.
Analyseartikel • Dec 16

Is Anupam Rasayan India (NSE:ANURAS) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
User avatar
Narrative-Update • Dec 14

ANURAS: Acquisition And Auditor Shift Will Pressure Sentiment Through 2026

Analysts have nudged their price target for Anupam Rasayan India slightly higher to ₹905.0 from ₹905, citing marginal improvements in the discount rate and long term profitability assumptions while keeping growth expectations largely intact. What's in the News Board meeting scheduled for December 09, 2025 to consider the acquisition of Monitchem Kansas S.à r.l and its subsidiaries, along with related loan receivable and Sale and Purchase Agreement approvals (company filing) Special shareholders meeting via postal ballot on January 09, 2026 to seek investor approval for the proposed acquisition and related resolutions (company filing) Special shareholders meeting via postal ballot on December 22, 2025, with voting conducted through remote e-voting (company filing) Board meeting held on November 21, 2025 to approve the postal ballot notice, set the cut-off date, define the e-voting window, and appoint a scrutinizer for the postal ballot process (company filing) Board meeting on October 17, 2025 to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing) Shareholders at the September 26, 2025 AGM approved the appointment of Natvarlal Vepari and Co., Chartered Accountants, Surat, as the company’s new statutory auditor (company filing) Valuation Changes Fair Value: Maintained effectively flat at ₹905.0, reflecting no material change in the intrinsic value estimate.
User avatar
Narrative-Update • Nov 30

ANURAS: Auditor Transition And Board Actions Will Pressure Sentiment Through 2025

Analysts have maintained their fair value estimate for Anupam Rasayan India at ₹905.00, citing stable forecast assumptions, even with minor adjustments in financial metrics. What's in the News The company scheduled a Special/Extraordinary Shareholders Meeting on December 22, 2025, to be conducted via postal ballot in India.
Analyseartikel • Nov 20

Anupam Rasayan India Ltd (NSE:ANURAS) Investors Are Less Pessimistic Than Expected

When you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...
User avatar
Narrative-Update • Nov 16

ANURAS: Net Profit Margin Will Weaken Amid Management And Auditor Changes

Analysts have slightly reduced their price target for Anupam Rasayan India to ₹905.00 per share, citing modest adjustments in profit margin expectations and valuation assumptions. What's in the News A board meeting is scheduled for October 17, 2025 to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 (Company Filing).
User avatar
Narrative-Update • Nov 01

ANURAS: Slowing Revenue Expansion Will Pressure Margins Despite Profit Recovery

Analysts have raised their price target for Anupam Rasayan India from ₹884.29 to ₹909.29, citing improved profit margin expectations even though projected revenue growth is expected to moderate. What's in the News The board meeting is scheduled for October 17, 2025, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2025 (Key Developments).
User avatar
Narrative-Update • Oct 18

Growing Contract Wins And Tightening Margins Will Shape Future Prospects

Analysts have revised their price target for Anupam Rasayan India upward from ₹838 to ₹884. They cited slight adjustments in the discount rate and an upward recalibration of fair value in their latest models.
Analyseartikel • Oct 02

Returns On Capital At Anupam Rasayan India (NSE:ANURAS) Have Hit The Brakes

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
User avatar
Narrative-Update • Aug 22

Expanding Pharma And Polymer Segments To Drive Future Success

Despite a notable reduction in consensus revenue growth forecasts, expectations for Anupam Rasayan India's earnings multiple have increased, resulting in a higher analyst price target now at ₹837.86. What's in the News Board meeting scheduled to consider and approve unaudited Q1 FY26 financial results.
Analyseartikel • May 28

Anupam Rasayan India Ltd Just Missed EPS By 7.1%: Here's What Analysts Think Will Happen Next

Investors in Anupam Rasayan India Ltd ( NSE:ANURAS ) had a good week, as its shares rose 3.0% to close at ₹991...
Analyseartikel • Apr 08

Anupam Rasayan India Ltd (NSE:ANURAS) Not Lagging Industry On Growth Or Pricing

When you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...
User avatar
Neues Narrative • Mar 11

Expanding Pharma And Polymer Segments To Drive Future Success

Pharma and Polymer growth, energy cost cuts, and a robust pipeline with new molecules will drive future revenue growth and improve net margins.
Analyseartikel • Nov 25

Anupam Rasayan India's (NSE:ANURAS) Problems Go Beyond Weak Profit

A lackluster earnings announcement from Anupam Rasayan India Ltd ( NSE:ANURAS ) last week didn't sink the stock price...
Analyseartikel • Nov 18

Earnings Report: Anupam Rasayan India Ltd Missed Revenue Estimates By 9.2%

The second-quarter results for Anupam Rasayan India Ltd ( NSE:ANURAS ) were released last week, making it a good time...
Analyseartikel • Nov 02

Anupam Rasayan India (NSE:ANURAS) Hasn't Managed To Accelerate Its Returns

There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Analyseartikel • Aug 24

Time To Worry? Analysts Just Downgraded Their Anupam Rasayan India Ltd (NSE:ANURAS) Outlook

Today is shaping up negative for Anupam Rasayan India Ltd ( NSE:ANURAS ) shareholders, with the analysts delivering a...
Analyseartikel • Aug 17

Anupam Rasayan India Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

As you might know, Anupam Rasayan India Ltd ( NSE:ANURAS ) last week released its latest quarterly, and things did not...
Analyseartikel • May 26

Anupam Rasayan India's (NSE:ANURAS) Shareholders Have More To Worry About Than Only Soft Earnings

A lackluster earnings announcement from Anupam Rasayan India Limited ( NSE:ANURAS ) last week didn't sink the stock...
Analyseartikel • May 22

Analyst Estimates: Here's What Brokers Think Of Anupam Rasayan India Limited (NSE:ANURAS) After Its Full-Year Report

Last week saw the newest annual earnings release from Anupam Rasayan India Limited ( NSE:ANURAS ), an important...
Analyseartikel • Dec 30

What You Can Learn From Anupam Rasayan India Ltd's (NSE:ANURAS) P/E

When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 29x, you may consider Anupam...
Analyseartikel • Nov 03

Anupam Rasayan India (NSE:ANURAS) Might Have The Makings Of A Multi-Bagger

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...

Aktionärsrenditen

ANURASIN ChemicalsIN Markt
7D-0.7%0.4%-0.6%
1Y12.4%-0.6%-0.1%

Rendite im Vergleich zur Industrie: ANURAS übertraf die Branche Indian Chemicals , die im vergangenen Jahr eine Rendite von -0.6 erzielte.

Rendite vs. Markt: ANURAS übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von -0.1 erzielte.

Preisvolatilität

Is ANURAS's price volatile compared to industry and market?
ANURAS volatility
ANURAS Average Weekly Movement1.7%
Chemicals Industry Average Movement5.9%
Market Average Movement5.7%
10% most volatile stocks in IN Market8.9%
10% least volatile stocks in IN Market3.4%

Stabiler Aktienkurs: ANURAS hatte in den letzten 3 Monaten im Vergleich zum Indian -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: ANURASDie wöchentliche Volatilität (2%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
19842,606Gopal Agrawalwww.anupamrasayan.com

Anupam Rasayan India Ltd ist in der Auftragssynthese und Herstellung von Spezialchemikalien in Indien, Europa, Japan, Singapur, China, Nordamerika und international tätig. Das Unternehmen ist in zwei Segmenten tätig: Spezialchemikalien für die Biowissenschaften und andere Spezialchemikalien. Das Unternehmen bietet Spezialchemikalien für die Biowissenschaften an, z. B. Agro-Zwischenprodukte und Agro-Wirkstoffe für die agrochemische Industrie, antibakterielle und UV-Schutz-Zwischenprodukte und -Inhaltsstoffe für die Körperpflegeindustrie sowie Zwischenprodukte und wichtige Ausgangsstoffe für pharmazeutische Wirkstoffe.

Anupam Rasayan India Ltd's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Anupam Rasayan India im Vergleich zum Marktanteil des Unternehmens?
ANURAS grundlegende Statistiken
Marktanteil₹139.99b
Gewinn(TTM)₹1.75b
Umsatz(TTM)₹25.35b
80.2x
Kurs-Gewinn-Verhältnis
5.5x
Kurs-Umsatz-Verhältnis

Ist ANURAS zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ANURAS Gewinn- und Verlustrechnung (TTM)
Einnahmen₹25.35b
Kosten der Einnahmen₹13.64b
Bruttogewinn₹11.71b
Sonstige Ausgaben₹9.96b
Gewinn₹1.75b

Zuletzt gemeldete Gewinne

Jun 30, 2026

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)15.35
Bruttomarge46.18%
Nettogewinnspanne6.89%
Schulden/Eigenkapital-Verhältnis41.3%

Wie hat sich ANURAS auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

0.1%
Aktuelle Dividendenrendite
10%
Ausschüttungsquote

Zahlt ANURAS eine zuverlässige Dividende?

Siehe ANURAS Dividendenhistorie und Benchmarks
Bis wann müssen Sie ANURAS kaufen, um eine kommende Dividende zu erhalten?
Anupam Rasayan India Dividendentermine
Ex-Dividenden DatumSep 18 2026
Datum der DividendenzahlungOct 29 2026
Tage bis Ex-Dividende7 days
Tage bis zum Datum der Dividendenzahlung48 days

Zahlt ANURAS eine zuverlässige Dividende?

Siehe ANURAS Dividendenhistorie und Benchmarks

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/09/10 12:46
Aktienkurs zum Tagesende2026/09/10 00:00
Gewinne2026/06/30
Jährliche Einnahmen2026/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
  • SEC-Formular 10-K
  • SEC-Formular 10-Q
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
  • Analysten Research Berichte
  • Blue Matrix
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
  • ICE-Marktdaten
  • SEC-Formular S-1
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
  • SEC-Formular 4
  • SEC-Formular 13D
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
  • SEC-Formular 10-K
  • SEC-Formular DEF 14A
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens
  • SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Anupam Rasayan India Ltd wird von 12 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Ankur PeriwalAxis Capital Limited
Satish KumarCGS International
Dane LeoneCGS International

Triff überall bessere Investmententscheidungen

Zum Herunterladen scannen
App Store öffnenGoogle Play öffnen
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
Datenquellen anzeigen
Märkte
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Ideen für Investitionen
  • Unterbewertete Unternehmen
  • Dividendenstarke Unternehmen
  • Insider-Käufe
  • Kernenergie
  • Autonome Fahrzeuge
  • Künstliche Intelligenz
  • Kryptowährung und Blockchain
  • Cybersicherheit
  • Weitere Ideen
Börsengemeinschaften
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Werkzeuge und Funktionen
  • Portfolio-Tracker
  • Aktien-Screener & Alarme
  • Erzählungen & faire Werte
  • Dividenden-Rechner
Nachrichten & Entdeckungen
  • Neueste Bestandsnachrichten
  • Globale Markteinsichten
  • Der Fuchsbau
  • Ideen für Investitionen
  • Community-Erzählungen
  • Was gibt's Neues?
Simply Wall St
  • Pläne & Preisgestaltung
  • Werbung},{
  • Über uns
  • Kontakt
  • Karriere
  • Hilfe-Center
  • Lernen Sie das Investieren in Aktien
  • Partnerprogramm
  • Business & Unternehmen
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Bedingungen und Konditionen
  • Datenschutzbestimmungen
  • KI-Bedingungen
  • Leitfaden für Finanzdienstleistungen